Your browser is no longer supported. Please, upgrade your browser.
MOR MorphoSys AG daily Stock Chart
MorphoSys AG
Index- P/E- EPS (ttm)-0.26 Insider Own- Shs Outstand31.56M Perf Week-4.46%
Market Cap723.90M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-13.27%
Income- PEG- EPS next Q- Inst Own7.30% Short Float- Perf Quarter-12.11%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio4.07 Perf Half Y-16.15%
Book/sh4.90 P/B4.68 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range21.75 - 35.90 Perf YTD-9.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.10% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low5.47% ATR0.70
Employees322 Current Ratio- Sales Q/Q265.70% Oper. Margin- RSI (14)32.07 Volatility2.39% 2.51%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close23.43
ShortableYes LT Debt/Eq- EarningsMar 13 AMC Payout- Avg Volume29.33K Price22.94
Recom- SMA20-7.90% SMA50-13.71% SMA200-17.49% Volume13,718 Change-2.09%
Nov-05-18Initiated Piper Jaffray Overweight
Sep-07-18Downgrade Berenberg Buy → Hold
May-14-18Initiated JMP Securities Mkt Outperform $38
Mar-19-19 05:40PM  MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma ACCESSWIRE
Mar-13-19 06:15PM  MorphoSys Presents Results for Fiscal Year 2018 ACCESSWIRE
Mar-07-19 04:55PM  MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL ACCESSWIRE
Mar-04-19 09:20AM  Invitation to Year-End Results 2018 Conference Call of MorphoSys AG on March 14, 2019 ACCESSWIRE
Feb-21-19 08:35AM  MorphoSys to Present at Upcoming Investor Conference ACCESSWIRE
Feb-19-19 07:35AM  Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire ACCESSWIRE
07:35AM  Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire ACCESSWIRE
Jan-31-19 12:55PM  MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab ACCESSWIRE +7.43%
Jan-28-19 03:19AM  European Shares Drop as Investors Await for Brexit, Fed, Trade Bloomberg -5.76%
Jan-26-19 07:50AM  MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab ACCESSWIRE
Jan-18-19 07:49AM  The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug Benzinga
Jan-17-19 04:25PM  MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis ACCESSWIRE
Dec-17-18 07:40AM  MorphoSys AG: Corporate Calendar 2019 ACCESSWIRE
Dec-07-18 07:21AM  MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis ACCESSWIRE
Dec-01-18 06:55PM  MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus Lenalidomide in r/r DLBCL at ASH 2018 ACCESSWIRE
Nov-26-18 12:51AM  MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis ACCESSWIRE
Nov-25-18 09:41AM  The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings Benzinga
Nov-21-18 07:13AM  MorphoSys to Present at Upcoming Investor Conferences ACCESSWIRE
Nov-20-18 08:29AM  The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings Benzinga
Nov-19-18 03:25PM  MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa ACCESSWIRE
Nov-16-18 08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-15-18 08:31PM  BRIEF-Morphosys, I-Mab Sign Agreement For Morphosys's Novel Immuno-Oncology Agent MOR210 Reuters
03:20PM  MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210 ACCESSWIRE
Nov-05-18 03:50PM  DGAP-News: MorphoSys AG Announces Third Quarter 2018 Results ACCESSWIRE -7.74%
Nov-01-18 10:20AM  MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting ACCESSWIRE +18.07%
Oct-21-18 07:07AM  MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference ACCESSWIRE
Oct-19-18 09:50AM  MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis ACCESSWIRE
Sep-27-18 08:30AM  MorphoSys to Present at Upcoming Investor Conferences ACCESSWIRE
Sep-25-18 04:20PM  MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients ACCESSWIRE
Sep-18-18 08:44AM  The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares Benzinga
03:52AM  LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics Business Wire
Sep-17-18 04:15PM  MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics ACCESSWIRE
Sep-13-18 04:45PM  MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging Study with MOR106 ACCESSWIRE
08:42AM  The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx Benzinga
04:33AM  MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R) Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis ACCESSWIRE
Sep-12-18 04:35PM  MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global License Agreement for MOR106 with Pharma Partner ACCESSWIRE
Sep-06-18 04:20AM  MorphoSys AG To Be Listed In MDAX ACCESSWIRE
Aug-21-18 08:25AM  MorphoSys to Present at Upcoming Investor Conferences ACCESSWIRE
Aug-07-18 09:15PM  DGAP-News: MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202 ACCESSWIRE
09:01PM  I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202 PR Newswire
Aug-02-18 06:00AM  MorphoSys AG to Host Earnings Call ACCESSWIRE
Aug-01-18 04:25PM  MorphoSys AG Reports Second Quarter 2018 Financial Results ACCESSWIRE
Jul-25-18 08:30AM  MorphoSys to Host Q2 2018 Conference Call on August 2, 2018 ACCESSWIRE
Jul-24-18 04:38PM  MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial ACCESSWIRE
Jul-20-18 07:53AM  Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2 Benzinga
Jul-19-18 08:59AM  MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Pharma Partner ACCESSWIRE
08:55AM  Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018 ACCESSWIRE
08:33AM  [$$] Novartis, MorphoSys and Galapagos Shares Rise on Drug Deal The Wall Street Journal
02:29AM  Novartis to Pay as Much as $1 Billion for Rights to Skin Drug Bloomberg
02:25AM  Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug Reuters
Jul-11-18 08:15AM  Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares Benzinga
Jul-10-18 04:25PM  MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn's Disease ACCESSWIRE
Jun-15-18 09:13AM  Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug Benzinga
02:59AM  MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference ACCESSWIRE
02:44AM  MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018 ACCESSWIRE
Jun-12-18 04:22PM  New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway ACCESSWIRE
Jun-04-18 10:10AM  MorphoSys to Present at Upcoming Investor Conferences ACCESSWIRE
May-31-18 02:54AM  Who Are The Top Investors In MorphoSys AG (ETR:MOR)? Simply Wall St.
May-21-18 10:47AM  Can MorphoSys AG (ETR:MOR) Improve Your Portfolio Returns? Simply Wall St.
May-18-18 08:50AM  MorphoSys to Present at Upcoming Investor Conferences ACCESSWIRE
May-17-18 04:25PM  Annual General Meeting of MorphoSys AG Elects New Supervisory Board Members ACCESSWIRE
09:20AM  MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Programs at Upcoming EHA 2018 Conference ACCESSWIRE
May-14-18 03:26PM  Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms Benzinga
10:32AM  3 New Healthcare Stocks to Buy Right Now InvestorPlace
03:27AM  Want To Invest In MorphoSys AG (ETR:MOR)? Heres How It Performed Lately Simply Wall St.
May-02-18 04:25PM  MorphoSys AG Reports First Quarter 2018 Results ACCESSWIRE
May-01-18 04:30PM  MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients ACCESSWIRE
Apr-26-18 04:30PM  MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea ACCESSWIRE
Apr-25-18 09:55AM  MorphoSys AG: Updated Corporate Calendar 2018 ACCESSWIRE
Apr-23-18 04:20PM  MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million ACCESSWIRE
Apr-19-18 04:24PM  Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market GlobeNewswire
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.